Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

The Journal of Urology
Gerald AndrioleREDUCE Study Group

Abstract

Chemoprevention may significantly impact the natural history of prostate cancer. The most potent intraprostatic androgen, dihydrotestosterone, has a significant role in the pathophysiology of prostate cancer. It represents a biologically plausible target for chemoprevention through the inhibition of 5alpha-reductase isoenzymes. The Reduction by Dutasteride of Prostate Cancer Events clinical trial is an international, multicenter, double-blind, placebo controlled chemoprevention study designed to determine if dutasteride 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. A total of 8,000 men will be randomized to receive dutasteride or placebo for 4 years. Eligible men must be 50 to 75 years old, have a serum prostate specific antigen of 2.5 to 10 ng/ml (ages 50 to 60 years) or 3.0 to 10 ng/ml (older than 60 years). Men must have a negative 6 to 12 core biopsy within 6 months prior to enrollment. Repeat biopsies will be taken at 2 and 4 years. The rates of prostate cancer for each treatment group will be compared. Genetic and protein biomarkers of prostate cancer, and the effect of dutasteride on benign prostatic hyperplasia and prostatitis symptomatology and histopathology will also be assessed. Results remai...Continue Reading

References

Aug 1, 1993·The Journal of Clinical Investigation·A E ThigpenD W Russell
Dec 1, 1996·The Journal of Steroid Biochemistry and Molecular Biology·N BruchovskyP S Rennie
Jul 23, 1999·The Journal of Steroid Biochemistry and Molecular Biology·C IehléP M Martin
Sep 28, 2002·Urology·Claus G RoehrbornUNKNOWN ARIA3001 ARIA3002 and ARIA3003 Study Investigators
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman

❮ Previous
Next ❯

Citations

May 8, 2007·Der Urologe. Ausg. A·B J Schmitz-DrägerR M Schäfer
Sep 18, 2007·Der Urologe. Ausg. A·B J Schmitz-DrägerG Lümmen
Jun 28, 2005·Current Urology Reports·Timothy B Hargreave, Alan S McNeill
Apr 18, 2009·Current Urology Reports·Janet L Colli, Christopher L Amling
Jun 18, 2010·Current Urology Reports·Haim Matzkin
May 20, 2008·Lancet·Jan-Erik Damber, Gunnar Aus
Nov 3, 2005·Nature Clinical Practice. Oncology·Edith D Canby-Hagino, Ian M Thompson
Feb 14, 2006·Nature Clinical Practice. Urology·Eric A Klein
Aug 12, 2006·Nature Clinical Practice. Urology·Manlio A Goetzl, Jeffrey M Holzbeierlein
Sep 12, 2006·Nature Clinical Practice. Urology·Michael Marberger
Jun 15, 2007·Nature Reviews. Cancer·Gary J Kelloff, Caroline C Sigman
Jun 2, 2011·Nature Reviews. Urology·Lucas P Nacusi, Donald J Tindall
May 27, 2009·Prostate Cancer and Prostatic Diseases·C G RoehrbornA Benedict
Mar 10, 2010·Prostate Cancer and Prostatic Diseases·M E StokesP Albertsen
Nov 3, 2005·Prostate Cancer and Prostatic Diseases·D C Gould, R S Kirby
Apr 2, 2010·The New England Journal of Medicine·Gerald L AndrioleUNKNOWN REDUCE Study Group
Dec 3, 2010·Japanese Journal of Clinical Oncology·Hideyuki AkazaUNKNOWN REDUCE Study Group
Sep 13, 2007·Journal of the National Cancer Institute·Gerald L AndrioleRobert L Grubb
Jun 17, 2006·La Revue du praticien·Arnauld Villers, Nicolas Berthon
Mar 23, 2013·Current Opinion in Oncology·Howard L ParnesJoseph A Tangrea
Feb 28, 2008·The Cancer Journal·Andrew C Hsieh, Charles J Ryan
Nov 13, 2010·International Journal of Clinical Practice·M T RosenbergM M Miner
Jan 18, 2006·Annual Review of Medicine·Eric A Klein
Feb 13, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Anne R SimoneauFrank L Meyskens
Dec 30, 2011·BMC Health Services Research·Michael E StokesYijian Huang
Mar 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barnett S KramerUNKNOWN American Urological Association Practice Guidelines Committee
Jun 26, 2010·Endocrine-related Cancer·Fazlul H SarkarDejuan Kong
Dec 1, 2007·Clinical Interventions in Aging·Steven J HudakIan M Thompson
Jan 27, 2012·Journal of Carcinogenesis·Maarten C Bosland, Abeer M Mahmoud
Nov 6, 2013·Annual Review of Medicine·Goutham VemanaStephen J Freedland
Feb 16, 2010·Asian Journal of Andrology·Louis J Gooren
Oct 30, 2014·Journal of Molecular Endocrinology·Ye ZhouJeremy O Jones
Jan 11, 2014·Asian Journal of Andrology·Lori A Cooper, Stephanie T Page
Dec 27, 2005·Expert Review of Anticancer Therapy·Naohiro FujimotoTetsuro Matsumoto
Jul 1, 2008·Expert Review of Anticancer Therapy·Mireia MusqueraAlexandre R Zlotta
Aug 5, 2009·Expert Opinion on Emerging Drugs·Kashif Siddiqui, Laurence H Klotz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.